EC concludes talks to secure coronavirus vaccine for Europeans

The Commission concluded on Friday exploratory talks with a pharmaceutical company to purchase a potential vaccine against Covid-19, the EU press service reported. The envisaged contract with Sanofi-GSK would provide for an option for all EU Member States to purchase the vaccine. It is envisaged that, once a vaccine has proven to be safe and effective, the EC would have a contractual framework in place for the purchase of 300 million doses, on behalf of all EU Member States.

“The European Commission does all in its power to ensure that Europeans have rapid access to a vaccine that is safe and protects them from coronavirus. Today's step with Sanofi-GSK is a first important cornerstone of a much broader European Vaccines Strategy,” EC President Ursula von der Leyen said. “A safe and effective Covid-19 vaccine is the surest exit strategy from the crisis. For that reason, we have been negotiating a united EU approach to secure doses of promising vaccine candidates in recent weeks.” Health Commissioner Stella Kyriakides added.

The exploratory talks are intended to result in an Advance Purchase Agreement to be financed with the Emergency Support Instrument, which has funds dedicated to the creation of a portfolio of potential vaccines with different profiles and produced by different companies.  

The Commission is also committed to ensuring that everyone who needs a vaccine gets it, anywhere in the world and not only at home. No one will be safe until everyone is safe. This is why it has raised almost €16bn since 4 May under the Coronavirus Global Response, the global action for universal access to tests, treatments and vaccines against coronavirus and for the global recovery.

Similar articles